Scholarlink

Background <p>Emotional distress (ED) has been demonstrated to compromise immune responses against tumors; however, few clinical studies have explored its influence on the efficacy of immune checkpoint inhibitors (ICIs) in cancer patients, especially those with gastroesophageal cancer (GEC). Additionally, reliable biomarkers for predicting the response to immunotherapy remain elusive. This study was aimed at investigating whether ED affects the outcomes of immunotherapy in advanced GEC patients and identifying potential biomarkers predictive of immunotherapy efficacy.</p> Methods <p>This prospective observational cohort study enrolled 84 patients with advanced, treatment-naïve, and inoperable GEC. ED was evaluated at baseline using the Patient Health Questionnaire-9 and the Generalized Anxiety Disorder 7-item Scale. The primary endpoint was Progression-Free Survival (PFS), while the secondary endpoint was Disease Control Rate (DCR).</p> Results <p>Patients with baseline ED exhibit significantly shorter median PFS (7.8 months vs. 14.0 months, HR = 2.59, 95% CI: 1.35-4.97, <i>P</i> = 0.004) and a lower DCR (39.5% vs. 68.3%, OR = 3.21, 95% CI: 1.29–7.98, <i>P</i> = 0.012) compared to those without ED. Exploratory analyses further demonstrate that both pre- and post-treatment peripheral inflammatory markers (PIMs) are independently and jointly associated with survival outcomes in combination with ED.</p> Conclusions <p>This prospective study demonstrates that ED and elevated PIMs significantly impair ICI efficacy in advanced GEC. The synergistic interaction between ED and PIMs suggests underlying psycho-inflammatory mechanisms affecting treatment outcomes. These findings establish the clinical importance of integrating routine psychological assessment and PIMs monitoring in cancer patients receiving immunotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pretreatment emotional distress and peripheral biomarkers predict immune checkpoint inhibitor response in people with advanced inoperable gastroesophageal cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月26日

查看全文
  • Runze Huang,
  • Guodong Nie,
  • Anlong Li,
  • Xueting Ding,
  • Mengqian Liu,
  • Ling Cheng,
  • Senbang Yao,
  • Han Ge,
  • Jiaying Chai,
  • Yingxue Jia,
  • Lijun Liu,
  • Zhonglian Huang,
  • Huaidong Cheng,
  • Mingjun Zhang

摘要

Background

Emotional distress (ED) has been demonstrated to compromise immune responses against tumors; however, few clinical studies have explored its influence on the efficacy of immune checkpoint inhibitors (ICIs) in cancer patients, especially those with gastroesophageal cancer (GEC). Additionally, reliable biomarkers for predicting the response to immunotherapy remain elusive. This study was aimed at investigating whether ED affects the outcomes of immunotherapy in advanced GEC patients and identifying potential biomarkers predictive of immunotherapy efficacy.

Methods

This prospective observational cohort study enrolled 84 patients with advanced, treatment-naïve, and inoperable GEC. ED was evaluated at baseline using the Patient Health Questionnaire-9 and the Generalized Anxiety Disorder 7-item Scale. The primary endpoint was Progression-Free Survival (PFS), while the secondary endpoint was Disease Control Rate (DCR).

Results

Patients with baseline ED exhibit significantly shorter median PFS (7.8 months vs. 14.0 months, HR = 2.59, 95% CI: 1.35-4.97, P = 0.004) and a lower DCR (39.5% vs. 68.3%, OR = 3.21, 95% CI: 1.29–7.98, P = 0.012) compared to those without ED. Exploratory analyses further demonstrate that both pre- and post-treatment peripheral inflammatory markers (PIMs) are independently and jointly associated with survival outcomes in combination with ED.

Conclusions

This prospective study demonstrates that ED and elevated PIMs significantly impair ICI efficacy in advanced GEC. The synergistic interaction between ED and PIMs suggests underlying psycho-inflammatory mechanisms affecting treatment outcomes. These findings establish the clinical importance of integrating routine psychological assessment and PIMs monitoring in cancer patients receiving immunotherapy.